-+ 0.00%
-+ 0.00%
-+ 0.00%

Eikon Therapeutics' EIK1001 combination shows 72.4% response rate in squamous lung cancer trial

PUBT·10/26/2026 10:04:36
Eikon Therapeutics' EIK1001 combination shows 72.4% response rate in squamous lung cancer trial
  • Eikon Therapeutics presented updated TeLuRide-005 results for EIK1001 in previously untreated advanced non-small cell lung cancer at the 2026 ESMO Congress.
  • EIK1001 combined with pembrolizumab and chemotherapy showed potentially durable responses, supporting continued evaluation in advanced lung cancer.
  • The combination was generally well tolerated, with a safety profile supporting outpatient administration.
  • The ongoing Phase 2/3 TeLuRide-008 trial is enrolling patients, with an interim dose-selection analysis expected in the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260600PRIMZONEFULLFEED9852428) on October 26, 2026, and is solely responsible for the information contained therein.